Published online before print November 13, 2003, doi: 10.1161/01.STR.0000102561.86835.17
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2003;34:2999.)
© 2003 American Heart Association, Inc.
Comments, Opinions, and Reviews |
Anticoagulation or Inferior Vena Cava Filter Placement for Patients With Primary Intracerebral Hemorrhage Developing Venous Thromboembolism?
From Elderly Care/GIM Elderly Care Department, St Thomas’ Hospital, London, UK.
Correspondence to Dr J. Kelly, Elderly Care/GIM Elderly Care Department, North Wing (9th Floor), St Thomas’ Hospital, Lambeth Palace Rd, Lambeth, London SE1 7EH UK. E-mail jameskelly{at}northbrookfm.fsnet.co.uk
 |
Abstract |
|---|
Top
Abstract
IntroductionBackground— Most patients with primary intracerebral hemorrhage developing clinically apparent proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) require treatment with either anticoagulants or inferior vena cava filter insertion. Although the latter probably reduces the immediate risk of incident or recurrent PE and surmounts the undefined risk of recurrent intracranial bleeding with anticoagulation, the issue of preventing further thrombus propagation is not addressed, and there are associated short- and long-term risks, including a greater incidence of recurrent DVT.
Summary of Review— There are no data from randomized trials to clarify optimum treatment in these patients; indeed, the feasibility of such studies is questionable. Hence, treatment decisions continue to be made on an individualized basis and should include assimilation of information on key factors such as time elapsed post-stroke and lobar versus deep hemispheric location of the index event, natural history studies demonstrating a two-fold risk of recurrent intracerebral hemorrhage in the former subgroup.
Conclusions— In patients selected for anticoagulation, data from nonstroke patients suggest that a 5- to 10-day course of full-dose low-molecular-weight heparin followed by 3 months of lower-dose low-molecular-weight heparin is at least as effective as warfarin and may be associated with fewer hemorrhagic complications.
Key Words: deep vein thrombosis • intracerebral hemorrhage • pulmonary embolism
|
Introduction |
|---|
Patients with primary intracerebral hemorrhage (PICH) who subsequently develop clinically apparent deep vein thrombosis (DVT) and/or pulmonary embolism (PE) present a particularly difficult therapeutic dilemma because they are perceived to be at substantial risk of recurrent fatal PE in the absence of treatment and of recurrent ICH if treated with anticoagulants. Insertion of an inferior vena cava (IVC) filter is an option if anticoagulants are withheld. However, although these devices probably reduce the likelihood of PE,1,2 they are associated with short- and long-term risks,1 and this approach does not address propagating thrombus load, so anticoagulants may subsequently be required in a substantial proportion of patients.3 No prospective studies have addressed the issue of clarifying optimum management in these patients, and given that the magnitude of each of these risks is uncertain, treatment decisions are necessarily empirical and vary widely.4
To review what is known about the epidemiology of venous thromboembolism (VTE) after PICH, its natural history, and the possible risks and benefits associated with different treatment strategies, we performed a Medline search entering the following search terms: intracerebral hemorrhage, cerebral hemorrhage, hemorrhagic stroke, deep vein thrombosis, pulmonary embolism, venous thromboembolism, inferior vena cava filters, and caval filters. Although definitive recommendations about treatment clearly cannot be made, it is hoped that these data will assist individualized decision making in this area of continuing uncertainty.
|
Epidemiology of Clinical VTE After PICH |
|---|
Studies reporting on the incidence of clinical VTE after stroke generally either have been restricted to patients with acute ischemic stroke (AIS) or have reported data in unselected stroke patients. The absolute risk of fatal PE in the first month after AIS has been
1% to 2% in recent years,5,6 with PE accounting for up to 17% of early deaths in investigations with high postmortem rates.5–8 Fatal PEs are unusual in the first week and are most common between weeks 2 and 4, peaking in incidence toward the end of the second week.6 In the Oxford Community Stroke Project, 3 of 66 patients (5%) with PICH died of PE within the first 30 days.9 Recent studies suggest that recognized, clinically apparent VTE occurs in 2% to 3% of AIS patients receiving aspirin with or without graded compression stockings within 10 to 14 days of onset.10–12 Assuming that clinical VTE is approximately as common after acute PICH as after AIS, and given that aspirin, which reduces clinical PE by 29% after AIS,13 is not used after PICH, the incidence of recognized, clinical VTE in the first month after PICH is likely to be 
2% to 3%.
Approximately 125 000 first or recurrent strokes occur annually in the United Kingdom.14 PICHs account for 10% of these15 and are associated with a 30-day mortality of 35% to 50%.9,16 Hence, clinical VTE occurs in several hundred persons with PICH annually in the United Kingdom, and perhaps 100 to 200 people with PICH succumb to PE.
|
Treatment Decisions in Patients With VTE After PICH: Playing the Odds |
|---|
Treatment decisions in patients with PICH developing clinical VTE are currently made on an empirical individual basis and entail evaluating the following factors: the expected morbidity and mortality in patients with PICH and VTE that is left untreated, the expected effectiveness of treatment with anticoagulation or IVC filter insertion on these end points, and the expected morbidity and mortality associated with either treatment option. The magnitude of each of these specific factors is uncertain. In some cases, an approximation may be arrived at by extrapolation of data from unselected patients, eg, the likely mortality from incident or recurrent PE associated with untreated DVT or PE; in others, there are few meaningful data to guide decision making, as when attempting to estimate the risk of recurrent intracerebral bleeding when anticoagulants are given after PICH. What is known about each of these factors is discussed next.
|
Morbidity and Mortality Associated With Untreated Clinical VTE After PICH |
|---|
An estimate of the morbidity and mortality that might be associated with untreated clinical VTE after PICH is central to the formulation of appropriate treatment decisions. Although no such data are available specifically for patients with PICH, data on the natural history of untreated clinical VTE are available from historical series of unselected general medical and surgical patients reported before 1960, before which anticoagulants were not considered mandatory after VTE. Pooled data from a number of such studies containing several thousand patients with clinical PEs and DVTs (which are proximal in most cases17,18) show that the overall risks of fatal PE in untreated PE (recognized and in whom survival to the point of diagnosis occurred) and treated PE were 26.6% and 2.6%, respectively, with corresponding figures for proximal DVT (PDVT) of 16.2% and 0.7%. Recurrent nonfatal PE occurred in 12.8% and 15.1% of untreated patients presenting with PE and DVT, respectively19 (see the Figure).
|
Two caveats should be kept in mind when these data from the preimaging era are interpreted. First, all cases of VTE were diagnosed clinically. Subsequent studies using objective diagnostic methods found that VTE was confirmed in fewer than half of the patients in whom it was suspected,20–22 so early series contain a proportion of patients with diagnoses other that VTE. It should be noted, however, that alternative diagnoses in patients presenting with symptoms suggestive of DVT are rarely life threatening, whereas those in patients presenting with symptoms suggesting PE, such as pneumonia and myocardial infarction, may well be. Therefore, early data probably do not overestimate the mortality associated with untreated DVT, but the situation regarding PE is less certain. Second, all of these series were retrospective; no information was given on how patients were selected for anticoagulation or conservative measures; and treatment regimes varied widely, in some cases consisting of only a few days’ therapy with heparin. Moreover, nonanticoagulated patients were kept on bedrest for periods of up to 40 days,23 which may have worsened outcomes.
Notably, several studies indicate that the case fatality rate of clinical PE in unselected (ischemic and hemorrhagic) stroke patients may be higher than in other clinical settings.24–26 Hence, on the basis of these data, it seems reasonable to conclude that untreated clinical PDVT after PICH would be associated with 10% to 20% risk of fatal PE and 10% to 20% risk of nonfatal clinical PE; corresponding figures for untreated recognized clinical PE would be 20% to 30% and 10% to 20%. A further concern in survivors of untreated VTE is the association with the postthrombotic syndrome, which was almost universal in patients surviving untreated clinical PDVT in historical series,27 the incidence of which has dropped to 30% in the anticoagulant era.28
From these data, a policy of leaving unselected patients with PICH thought to have an otherwise reasonable prognosis who develop clinical VTE untreated is unacceptable. However, given the likely risks associated with both anticoagulation and IVC filters in these patients, might it be possible to identify selected subgroups with VTE in whom an observational brief might be justified?
|
Withholding Treatment in Selected Patients With PICH and Clinical VTE |
|---|
Observation only is probably justified in 1 subgroup of patients with clinical DVT and might be justified in another with PE. Ten percent to 20% of clinical DVTs are below the knee as opposed to proximal.17,18 Although PEs can arise from nonextending below-knee DVTs,29 they are very unlikely to be life threatening in the presence of adequate cardiorespiratory reserve20,30–35 (the Table), with an incidence of clinically important PE of probably
1% in untreated cases.33,36–41 Hence, PDVT and below-knee DVT are subgroups with distinct prognoses,32 and the main concern in patients with isolated below-knee DVT is the 20% risk of proximal propagation in untreated cases.39,42 Although it would be usual to treat unselected patients with symptomatic below-knee DVT, withholding treatment is considered safe if cardiorespiratory reserve is adequate (enabling them to survive a potential small PE from a below-knee source) as long as serial noninvasive imaging over the next fortnight excludes proximal propagation.17,20,32,34,42 Hence, given the potential risks associated with treatment, observation only would be reasonable in patients with PICH and clinical DVT confined to below the popliteal vein as long as cardiorespiratory reserve was adequate and ultrasound at 1 and 2 weeks did not show propagation to the proximal segment.
|
Two recent major studies have suggested that it may be possible to identify a subgroup of good-prognosis patients with PE who may have a relatively benign outlook in the absence of treatment and highlight the prognostic importance of residual PDVT and cardiorespiratory reserve. Hull et al31 withheld treatment in 627 patients from a larger cohort of unselected patients presenting with clinically suspected PE who had indeterminate ventilation-perfusion (VQ) scans, adequate cardiorespiratory reserve (the Table), and serially negative impedance plethysmography for residual PDVT over a 2-week period. Recurrent VTE occurred in only 1.9% at 3 months, including 1 fatal PE. Subsequently, Wells et al43 investigated a cohort of 665 patients with nonhigh clinical suspicion for PE, indeterminate VQ scans, and negative serial ultrasound examinations for PDVT over 2 weeks (performed on days 1, 3, 7, and 14) and showed that the 3-month incidence of clinical nonfatal VTE was only 0.5%. Both of these studies contained inpatients and outpatients, including a proportion with immobility, and clearly a significant minority of patients in whom treatment was withheld had sustained a PE. Stein et al35 retrospectively combined data from these reports to show that patients with nonmassive PE, adequate cardiopulmonary reserve, and negative serial ultrasounds over 2 weeks who were left untreated could be expected to have 3-month incidences of fatal and nonfatal recurrent PE of 0% and 3% and concluded that good-risk patients with PE who are at high risk of bleeding might safely be left untreated, an approach requiring prospective validation.44 Hence, withholding treatment in patients with clinical PE after PICH who fulfill these criteria might be an acceptable option, although it remains untested.
|
How Effectively Do Anticoagulants Prevent Morbidity and Mortality in Clinical VTE? |
|---|
The effectiveness of anticoagulants in the treatment of VTE was first demonstrated in 1960 by Barritt and Jordan,45 who randomized 35 patients with PE to anticoagulation plus bedrest or bedrest only. Five of 19 untreated patients (26.5%) died of recurrent PE, and another 5 (26.5%) developed nonfatal recurrence, where 0 of the 16 treated patients developed PE (for recurrent fatal and nonfatal PE, P=0.0005). However, although widely cited as supporting the effectiveness of anticoagulation in patients with VTE, the methodology of the trial has been criticized on a number of counts,46 so the main evidence for the effectiveness of anticoagulants is derived from a comparison of the outcomes of untreated VTE in historical series to treated VTE in historical and modern series (data summarized in Reference 19).
The historical data have been discussed. The best data on the outcome associated with treated VTE in unselected patients in the modern era come from an overview of 25 prospective studies published between 1966 and 1997 reporting on outcomes in patients with objectively diagnosed clinical VTE treated with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) followed by oral anticoagulants for 3 months.47 Data were available on 4221 patients presenting with DVT and 1302 with PE. During 3 months of treatment, 0.4% and 1.5%, respectively, suffered fatal PEs. In addition, 3.8% of patients presenting with DVT developed nonfatal recurrent VTE over this period, although comparable data were not available for those presenting with PE. In a more recent study48 of 1021 patients with VTE treated with either UFH or LMWH followed by oral anticoagulants for 3 months, recurrent fatal PE occurred in 2.2% of patients presenting with PE versus 0% of those presenting with DVT, whereas recurrent nonfatal events occurred in 4% and 5%, respectively. Pooled data from these studies show that treated patients presenting with DVT have a 3-month risk of fatal and nonfatal PE of 0.3% and 3.9%, respectively; corresponding figures in patients presenting with PE are 1.7% and 4.1%. Hence, fatal PE is an uncommon event in patients with VTE once anticoagulants are begun (outcomes of untreated/treated VTE are illustrated in the Figure).
|
How Effectively Do IVC Filters Prevent Morbidity and Mortality in Clinical VTE? |
|---|
IVC filters have been available for >3 decades49 and have been inserted percutaneously since 1984.50 The principal indication for placement is a strict contraindication to or failure of anticoagulant therapy.51 The only randomized trial of filters was performed by Decousus et al,2 who randomized 400 patients with symptomatic PDVT with or without concomitant symptomatic PE considered to be at high risk of incident or recurrent PE to treatment with anticoagulants alone or in combination with IVC filter placement; 4 different kinds of filters were used, and anticoagulants were given for
3 months. VQ scanning with or without pulmonary angiography was performed at baseline and 8 to 12 days later. Although PE (symptomatic plus asymptomatic) between days 8 and 12 was significantly more common in the anticoagulant only group (4.8 versus 1.1% p: 0.03), the difference in symptomatic events was not significant; cumulative symptomatic PE at 24 months did not differ significantly between the groups (3.4% versus 6.3% favoring the IVC filter group); and overall 2-year mortality was similar. Furthermore, the cumulative incidence of recurrent DVT at 2 years was significantly higher in the filter group at 20.8% versus 11.6% (P=0.02). Hence, although IVC filters may reduce the short-term risk of PE in patients receiving concomitant anticoagulation, this reduction comes at the cost of increasing the long-term risk of recurrent DVT if long-term anticoagulation is not used. Most of the data on the risks and benefits of IVC filters come from predominantly retrospective reviews of case series containing variable proportions of patients not given anticoagulants. Streiff et al1 recently reviewed the literature on the 5 types of filters available in the United States with mean follow-ups of 6 to 18 months and found that symptomatic PE occurred in 2.6% to 3.8%, but no type of filter could be identified as superior because of the absence of randomized comparisons. Although these data support the concept that IVC filters reduce (but do not eliminate) the risk of PE, there have been no studies comparing the effectiveness of IVC filters (without anticoagulation) in the main patient group of interest—those in whom filters are used as an alternative to anticoagulation.
|
Risks Associated With Anticoagulation in Patients With VTE After PICH |
|---|
In unselected patients with VTE, the excess risk of intracranial bleeding associated with a 3-month course of treatment with anticoagulants is
0.1%,52 although the equivalent risk in patients with PICH is unknown. However, the annual baseline risk or recurrent ICH in patients presenting with an index PICH is known.
In a systematic review53 of 10 prospective studies published between 1982 and 2000 investigating the natural history of recurrence in 1880 patients with PICH who survived for 30 days and were followed for a mean of 3.4 years, the annual rate of recurrent ICH was 2.3%. The only factor that consistently predicted a higher recurrence rate was lobar location of the incident event. On the basis of data from 1015 patients in 4 studies, patients with lobar hemorrhage had higher annual recurrence rates of 4.4% (95% confidence interval [CI], 3.1 to 6.3) versus 2.1% (95% CI, 1.6 to 2.7) in patients with deep hemispheric hemorrhages (P=0.002), presumably reflecting a higher incidence of underlying cerebral amyloid angiopathy in the former group.54,55 Recurrent intracranial hemorrhage had a higher mortality than the index event at 70%.54 Only 3 of the studies provided data on recurrence rates over time9,54,56 which were generally higher in the first year or 2 after the index bleed than in subsequent years. Two of these studies provided data on recurrence rates in the first 3 or so months from stroke onset. In the Oxford Community Stroke Project, 1 of 66 patients (1.5%) with PICH rebled in the first 3 months9; in the other study, 4 of 989 patients (0.4%) rebled within 4 months of onset.56 Pooling these data gives a 0.5% recurrence rate in the first 3 to 4 months after PICH. Approximately 25% of the patients in these studies had lobar PICH compared with 75% with deep hemispheric PICH. The relationship between location of the index bleed in the brain stem or cerebellum, which accounts for 10% to 15% of PICHs,54,57–62 and risk of rebleeding was not examined, although in 1 study published subsequent to this systematic review, it was associated with a similar risk of rebleeding to the group as a whole.61
The only prospective study of anticoagulants after PICH included 46 patients randomized to UFH 5000 U tid started on either day 4 or 10 after onset and given for an unspecified period of time.63 The latter subgroup were considered controls because this strategy was standard practice on the unit before the trial. Three of 23 controls rebled compared with 1 of 23 patients given UFH on day 4; all cases of rebleeding were associated with a fatal outcome. The authors concluded that low-dose UFH started on day 4 "did not increase the risk of re-bleeding" compared with standard practice. However, this study provides no information about the safety of low-dose UFH after PICH because there was no placebo group, so results could be interpreted as showing that both regimes were equally safe or equally unsafe. Subsequently, another 22 patients were added to this series who were treated from day 2 after onset64 with no additional cases of rebleeding. Given the absence of a placebo group, very small sample size, and different dosing regimen used, these data provide little useful information on the issue of the safety of using full-dose anticoagulants after PICH.
A single retrospective study provides limited information about outcomes in patients with intracranial bleeding given full-dose anticoagulants. In a study of patients with first PICH admitted to 3 hospitals between 1986 to 1995 who returned to their own homes,61 a subgroup of 22 patients started on anticoagulants after the index admission (5 for prosthetic heart valves, 4 for atrial fibrillation, 10 for arterial occlusive disease, and 3 for PE) was identified. More than half of the patients who survived were discharged to nursing homes, and these patients were excluded from the study. The odds ratio for recurrent intracerebral hemorrhage was 2.7 (95% CI, 0.9 to 7.8) in this subgroup. However, these data are of very limited value in predicting anticoagulant risk in patients with PICH because the patients studied were a selected group with good outcome and may have been at lower risk of anticoagulant-associated intracranial bleeding because incident hematoma size strongly correlates with outcome.57,59,62 Furthermore, no information was given as to how patients were selected for anticoagulation, and the subgroup receiving anticoagulants was very small.
Finally, prospective and retrospective studies have shown that low-dose heparin is safe in neurosurgical patients65; small retrospective series have shown that low-dose heparin appears safe in patients with traumatic brain injury66 and that full anticoagulation appears to be acceptably safe in patients with intracranial malignancy67–71 who develop VTE and when given to patients with cerebral venous sinus thrombosis associated with ICH.72 Furthermore, experiments with rats have shown that the risk of intracranial bleeding after craniotomy with full anticoagulation falls progressively as the number of days after surgery increases and that anticoagulation can safely be started 10 to 14 days postoperatively.73
The risks of extracranial bleeding when anticoagulants are given to patients who develop VTE after PICH are unknown. However, the risk of major bleeding in an overview of 11 studies of unselected patients with VTE anticoagulated for 3 months was 3%, the great majority of which were extracranial.74 The risk of bleeding is greatest during the first month of treatment.52 Furthermore, not all bleeds may be attributable to anticoagulation itself.52
In summary, the only conclusion that can be drawn from these data is that the risk of intracranial bleeding associated with a 3-month course of anticoagulants after PICH is an unknown multiple of the baseline risk of rebleeding. In patients presenting with nonlobar PICH, this baseline risk may be 0.5%.9,56 In those with a lobar index PICH, this risk may be approximately twice as high53 at 1%. Hence, treatment of clinical VTE after PICH with anticoagulants could result in a spectrum of risk-to-benefit ratios ranging from substantial benefit to possible harm.
|
Is Treatment of VTE With Therapeutic-Dose LMWH Safer Than Treatment With Oral Anticoagulants? |
|---|
Data from 6 studies75–80 containing 1184 patients with DVT (20% of whom also had signs or symptoms of PE) comparing treatment of VTE with 5 to 10 days of full-dose LMWH or UFH followed by oral anticoagulation with warfarin or acenocoumarol or with lower-dose LMWH maintenance therapy (eg, enoxaparin 40 mg once daily76,78,79) for
3 months were pooled in a meta-analysis in 2001.81 In patients receiving maintenance LMWH, odds ratios for recurrent DVT and PE were 0.77 (95% CI, 0.43 to 1.35) and 0.6 (95% CI, 0.24 to 1.49); those for major and minor bleeding were 0.73 (95% CI, 0.28 to 1.91) and 0.28 (95% CI, 0.16 to 0.48). Recurrent VTE between 4 and 12 months occurred in 7.7% of the LMWH group compared with 5.2% of the oral anticoagulants group (odds ratio, 1.6; 95% CI, 0.8 to 3.0). In a subsequent study,82 146 patients with DVT and/or PE and cancer—a subgroup at particularly high risk of both recurrent VTE and bleeding—were randomized to 3 months of treatment with enoxaparin (1.5 mg/kg once daily) or initial treatment with enoxaparin followed by 3 months of warfarin. Major hemorrhage or recurrent VTE occurred in 15 of the warfarin-treated patients (21.1%) versus 7 (10.5%, P=0.09) of the enoxaparin group, including fatal bleeding in 6 (8.0%) versus 0 (P=0.03). Two other studies published subsequent to the meta-analysis show concordant results.83,84 These data raise the possibility that the predictable anticoagulant response with LMWHs might make them a theoretically attractive alternative to warfarin in the ongoing treatment of VTE in patients at high risk of bleeding and/or recurrence.80,81,85 Hence, although definitive data are lacking, LMWH might be considered an alternative to warfarin when VTE occurs after PICH. |
Risks Associated With IVC Filter Placement in Patients With VTE After PICH |
|---|
The increased long-term risk of DVT in the trial of Decousus et al2 has been discussed. Examination for filter patency was performed in the 37 patients with filters who developed symptomatic recurrent VTE during the 2-year period of this study, and filter thrombosis was found in 16. In the overview by Streiff,1 DVT (clinical and subclinical) occurred in 6% to 32% of patients with filters, IVC filter thrombosis in 3.6% to 11.2% (clinical and subclinical), and symptomatic insertion site thrombosis in 7% to 17%. Filter migration, IVC penetration, or filter fracture occurred in a minority of patients who underwent radiological surveillance, although events were rarely symptomatic. Postthrombotic syndrome, which can have a significant negative impact on quality of life,86,87 is a further potential complication, although follow-up has generally been too short to ascertain its incidence accurately. In another review, it was found that filter-related complications were rarely life threatening, with deaths caused by filter complications occurring in 0.16% of patients in the reviewed studies.50
|
Is a Trial of Anticoagulation Versus Filter Placement in VTE After PICH Feasible? |
|---|
Resolution of uncertainty about optimum treatment of patients with PICH and clinical VTE would require a multicenter trial in which patients were randomized to either treatment with anticoagulation or IVC filter placement with follow-up to ascertain recurrent VTE, intracranial and extracranial bleeding, overall mortality, and the proportion of patients treated with filters who subsequently require anticoagulation because of recurrent thrombosis. Longer-term follow-up is required to monitor rates of recurrent DVT and postthrombotic syndrome. However, there are 2 major difficulties in performing such a trial.
First, patients with PICH who develop clinical VTE are relatively rare. The average district general hospital would be expected to admit 30 to 40 patients with PICH annually,16 up to half of whom die within the first month.9 Hence, 1 case of PICH complicated by clinical VTE might be encountered every 1 to 2 years in such a hospital. Therefore, cooperation from a large number of centers would be required, and maintaining enthusiasm for such a study over a prolonged period of time would be highly problematic.
Second, a simple strategy of randomization to anticoagulation or filter placement that did not take into account factors likely to influence the risk of recurrent intracranial bleeding such as lobar or nonlobar location of PICH and time elapsed since the index event would arguably belie the complexity and individualization of the decision-making process in these patients. Furthermore, an attempt to address this by applying a trial to a more targeted subgroup would further compound the problem of recruitment. Considering all of these factors, the feasibility of such a trial seems doubtful.
|
Conclusions |
|---|
There is no immediate prospect of resolving uncertainty about the optimum treatment of clinical VTE on a background of PICH in a randomized trial. However, prospective data derived in unselected patients on such issues as identification of good-prognosis patients with PE in whom treatment could safely be withheld, the short- and long-term safety and effectiveness of IVC filters as an alternative to anticoagulants, and alternatives to warfarin for the secondary prevention of VTE are likely to be forthcoming and may help inform treatment decisions. In the interim, clinical management decisions will continue to be individualized and frequently difficult.
Received June 12, 2003; revision received July 11, 2003; accepted August 21, 2003.
|
References |
|---|
1. Streiff MB. Vena caval filters: a comprehensive review. Blood. 2000; 95: 3669–3677.
2. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998; 338: 409–415.
3. Tardy B, Mismetti P, Page Y, Decousus H, Da Costa A, Zeni F, Barral G, Bertrand JC. Symptomatic inferior vena cava filter thrombosis: clinical study of 30 consecutive cases. Eur Respir J. 1996; 9: 2012–2016.[Abstract]
4. Cohen DL. Treating thrombotic complications in patients with primary intracerebral haemorrhage. J Royal Coll Phys. 1998; 32: 417–419.
5. Bounds JV, Wiebers DO, Whisnant JP, Okazaki H. Mechanisms and timing of deaths from cerebral infarction. Stroke. 1981; 12: 474–477.
6. Viitanen M, Winblad B, Asplund K. Autopsy-verified causes of death after stroke. Acta Med Scand. 1987; 222: 401–408.[Medline] [Order article via Infotrieve]
7. Scmidt E, Smirnov, Ryabova V. Results of the seven-year prospective study of stroke patients. Stroke. 1988; 19: 942–949.
8. Silver FL, Norris JW, Lewis AJ, Hachinski VC. Early mortality following stroke: a prospective study. Stroke. 1984; 15: 492–496.
9. Counsell C, Boonyakarnkul S, Dennis M, Sandercock P, Bamford J, Burn J, Warlow C. Primary intracerebral haemorrhage in the Oxfordshire Community Stroke Project. Cerebrovasc Dis. 1995; 5: 26–34.[CrossRef]
10. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997; 349: 1569–1581.[CrossRef][Medline] [Order article via Infotrieve]
11. Bath PM, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson J, O’Neill D, Orgogozo J, et al, for the TAIST investigators. Tinzaparin in Acute Ischaemic Stroke (TAIST): a randomised aspirin-controlled trial. Lancet. 2001; 358: 702–710.[CrossRef][Medline] [Order article via Infotrieve]
12. Berge E, Abdelnoor M, Nakstad PH, Sandset PM, for the HAEST Study Group. Low molecular weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. Lancet. 2000; 355: 1205–1210.[CrossRef][Medline] [Order article via Infotrieve]
13. Gubitz G, Sandercock P, Counsell C. Antiplatelet therapy for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library. Oxford, UK: Update Software; issue 1; 2001.
14. Sudlow CL, Warlow CP, for the International Stroke Incidence Collaboration. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. Stroke. 1997; 28: 491–499.
15. Bamford J, Dennis M, Sandercock P, Burn J, Warlow C. The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project. J Neurol Neurosurg Psychiatry. 1990; 53: 824–829.
16. Cohen DL. Cerebral hemorrhage. Age Ageing. 2000; 29: 547–549.
17. ACCP Consensus Committee on Pulmonary Embolism. Opinions regarding the diagnosis and management of venous thromboembolic disease. Chest. 1996; 109: 233–237.
18. Cogo A, Lensing AW, Prandoni P, Hirsh J. Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Arch Intern Med. 1993; 153: 2777–2780.
19. Kelly JA, Hunt BJ. Do anticoagulants improve survival in patients presenting with venous thromboembolism? J Intern Med. In press.
20. Hirsh J, Hull RD, Raskob GE. Diagnosis of pulmonary embolism. J Am Coll Cardiol. 1986; 8: 128B–136B.[Medline] [Order article via Infotrieve]
21. Ramsay LE. Impact of venography on the diagnosis and management of deep vein thrombosis. BMJ. 1983; 286: 698–699.
22. Simpson FG, Robinson PJ, Bark M, Losowsky MS. Prospective study of thrombophlebitis and "pseudothrombophlebitis." Lancet. 1980; 1: 331–333.[CrossRef][Medline] [Order article via Infotrieve]
23. Hermann RE, Davis JH, Holden WD. Pulmonary embolism: a clinical and pathological study with emphasis on the effect of prophylactic therapy with anticoagulants. Am J Surg. 1961; 102: 19–28.[CrossRef][Medline] [Order article via Infotrieve]
24. Kumasaka N, Sakuma M, Shirato K. Clinical features and predictors of in-hospital mortality in patients with acute and chronic pulmonary thromboembolism. Intern Med. 2000; 39: 1038–1043.[Medline] [Order article via Infotrieve]
25. Siddique RM, Siddique MI, Connors AF, Rimm AA. Thirty day case fatality rates for pulmonary embolism in the elderly. Arch Intern Med. 1996; 156: 2343–2347.
26. Wijdicks EF, Scott JP. Pulmonary embolism associated with acute stroke. Mayo Clin Proc. 1997; 72: 297–300.[Abstract]
27. Zilliacus H. On the specific treatment of thrombosis and pulmonary embolism with anticoagulants, with a particular reference to the post thrombotic sequelae. Acta Med Scand. 1946; 170: 1–221.
28. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistina P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996; 125: 1–7.
29. Doyle DJ, Turpie AG, Hirsh J. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med. 1987; 107: 441–445.
30. Dalen JE. When can treatment be withheld in patients with suspected pulmonary embolism? Arch Intern Med. 1993; 153: 1415–1418.
31. Hull RD, Raskob GE, Ginsberg JS, Panju AA, Brill-Edwards P, Coates G, Pineo GF. A non-invasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Intern Med. 1994; 154: 289–297.
32. Hull RD, Pineo GF. Disorders of Thrombosis. Philadelphia, PA: WB Saunders Co; 1995.
33. Raskob GE. Calf-vein thrombosis. In: Hull R, Raskob G, Pineo G, eds. Venous Thromboembolism: An Evidence-Based Atlas. Armonk, NY: Futura Publishing Co; 1996: 307–313.
34. Salzman EW. Venous thrombosis made easy. N Engl J Med. 1986; 314: 847–848.[Medline] [Order article via Infotrieve]
35. Stein PD, Hull RD, Raskob GE. Withholding treatment in patients with acute pulmonary embolism who have a high risk of bleeding and negative serial non-invasive leg tests. Am J Med. 2000; 109: 301–306.[CrossRef][Medline] [Order article via Infotrieve]
36. Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of postoperative deep vein thrombosis. Lancet. 1969; 2: 230–232.[CrossRef][Medline] [Order article via Infotrieve]
37. Solis MM, Ranval TJ, Nix ML, Eidt JF, Nelson CL, Ferris EJ, Lavender RC, Barnes RW. Is anticoagulation indicated for asymptomatic postoperative calf vein thrombosis? J Vasc Surg. 1992; 16: 414–419.[CrossRef][Medline] [Order article via Infotrieve]
38. Douss TW. The clinical significance of venous thrombosis of the calf. Br J Surg. 1976; 63: 377–378.[Medline] [Order article via Infotrieve]
39. Philbrick JT, Becker DM. Calf deep venous thrombosis: a wolf in sheep’s clothing. Arch Intern Med. 1988; 148: 2131–2138.
40. Moser KM, LeMoine JR. Is embolic risk conditioned by location of post-operative deep vein thrombosis? Ann Intern Med. 1981; 94: 439–444.[Medline] [Order article via Infotrieve]
41. Clarke-Pearson DL, Synan IS, Coleman RE, Hinshaw W, Creasman WT. The natural history of postoperative venous thromboemboli in gynecologic oncology: a prospective study of 382 patients. Am J Obstet Gynecol. 1984; 148: 1051–1054.[Medline] [Order article via Infotrieve]
42. Giannoukas AD, Labropoulos N, Burke P, Katsamouris A, Nicolaides AN. Calf deep venous thrombosis: a review of the literature. Eur J Vasc Endovasc Surg. 1995; 10: 398–404.[CrossRef][Medline] [Order article via Infotrieve]
43. Wells PS, Ginsberg JS, Anderson DR, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med. 1998; 129: 997–1005.
44. Hambleton J. Anticoagulation in high-risk patients: when is this approach not worth the risk? Am J Med. 2000; 109: 335–337.[CrossRef][Medline] [Order article via Infotrieve]
45. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. Lancet. 1960; 3: 1309–1312.
46. Egermayer P. Value of anticoagulants in the treatment of pulmonary embolism: a discussion paper. J Royal Soc Med. 1981; 74: 675–681.[Medline] [Order article via Infotrieve]
47. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998; 279: 458–462.
48. Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med. 2000; 160: 3431–3436.
49. Ferris EJ, McCowan TC, Carver DK, McFarland DR. Percutaneous inferior vena cava filters: follow-up of seven designs in 320 patients. Radiology. 1993; 188: 851–856.
50. Becker DM, Philbrick JT, Selby JB. Inferior vena cava filters. Arch Intern Med. 1992; 152: 1985–1994.
51. Hyers TM, Agnelli G, Hull RD. Antithrombotic therapy for venous thromboembolic disease. Chest. 1998; 114 (suppl): 561S–578S.
52. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep venous-thrombosis. Am J Med. 1999; 107: 414–424.[CrossRef][Medline] [Order article via Infotrieve]
53. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracerebral hemorrhage. Neurology. 2001; 56: 773–777.
54. Passero S, Burgalassi L, D’Andrea P, Battistini N. Recurrence of bleeding in patients with primary intracerebral hemorrhage. Stroke. 1995; 26: 1189–1192.
55. Cosgrove GR, Leblanc R, Meagher-Villemure K, Ethier R. Cerebral amyloid angiopathy. Neurology. 1985; 35: 625–631.
56. Bae H, Jeong D, Doh J, Lee K, Yun I, Byun B. Recurrence of bleeding in patients with hypertensive intracerebral hemorrhage. Cerebrovasc Dis. 1999; 9: 102–108.[CrossRef][Medline] [Order article via Infotrieve]
57. Helweg-Larsen S, Sommer W, Strange P, Lester J, Boysen G. Prognosis for patients treated conservatively for spontaneous intracerebral hematomas. Stroke. 1984; 15: 1045–1048.
58. Hill MD, Silver FL, Austin PC, Tu JV. Rate of stroke recurrence in patients with primary intracerebral hemorrhage. Stroke. 2000; 31: 123–127.
59. Fieschi C, Carolei A, Fiorelli M, Argentino C, Bozzao L, Fazio C, Salvetti M, Bastianello S. Changing prognosis of primary intracerebral hemorrhage: results of a clinical and computed tomographic follow-up study of 104 patients. Stroke. 1988; 19: 192–195.
60. Fogelholm R, Nuutila M, Vuorela AL. Primary intracerebral hemorrhage in the Jyvaskyla region, central Finland, 1985–89: incidence, case fatality rate, and functional outcome. J Neuro Neurosurg Psychiatry. 1992; 55: 546–552.
61. Vermeer SE, Algra A, Franke CL, Koudstaal PJ, Rinkel GJ. Long-term prognosis after recovery from primary intracerebral haemorrhage. Neurology. 2002; 59: 205–209.
62. Douglas MA, Haerer AF. Long-term prognosis of hypertensive intracerebral hemorrhage. Stroke. 1982; 13: 488–491.
63. Dickmann U, Voth E, Schicha H, et al. Heparin therapy, deep vein thrombosis and pulmonary embolism after intracerebral haemorrhage. Klin Wochenschr. 1998; 66: 1182–1183.
64. Boeer A, Voth E, Henze T, Prange HW. Early heparin therapy in patients with spontaneous intracerebral hemorrhage. J Neurol Neurosurg Psychiatry. 1991; 54: 466–467.
65. Hamilton MG, Hull RD, Pineo GF. Venous thromboembolism in neurosurgery and neurology patients: a review. Neurosurgery. 1994; 34: 280–296.[Medline] [Order article via Infotrieve]
66. Kim J, Gearhart MM, Zurick A, Zuccarello M, James L, Luchette FA. Preliminary report on the safety of heparin for deep vein thrombosis prophylaxis after severe head injury. J Trauma. 2002; 53: 38–43.[Medline] [Order article via Infotrieve]
67. Levin JM, Schiff D, Loeffler JS, Fine HA, Black P, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993; 43: 1111–1114.
68. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Beven EG, Bay JW. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Arch Intern Med. 1987; 147: 2177–2179.
69. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 1994; 73: 493–498.[CrossRef][Medline] [Order article via Infotrieve]
70. Choucair AK, Silver P, Levin VA. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg. 1987; 66: 357–358.[Medline] [Order article via Infotrieve]
71. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol. 1983; 13: 334–336.[CrossRef][Medline] [Order article via Infotrieve]
72. Fink JN, McAuley DL. Safety of anticoagulation for cerebral venous thrombosis associated with intracerebral hematoma. Neurology. 2001; 57: 1138–1139.
73. Lazio BE, Simard JM. Anticoagulation in neurosurgical patients. Neurosurgery. 1999; 45: 838–847.[Medline] [Order article via Infotrieve]
74. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 1998; 114: 511S–523S.
75. Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, Filipecki S, Michalak J, Ciesielski L, Mackiewicz Z, Czestochowska E, et al. Low molecular weight heparin versus acenocoumarol in the secondary prevention of deep vein thrombosis. Thromb Haemost. 1999; 81; 26–31.[Medline] [Order article via Infotrieve]
76. Pini M, Aiello S, Manotti C, Pattachini C, Quintavalla R, Poli T, Tagliaferri A, Dettori AG. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost. 1994; 72: 191–197.[Medline] [Order article via Infotrieve]
77. Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg. 1996; 20: 521–527.[CrossRef][Medline] [Order article via Infotrieve]
78. Velga F, Escriba A, Maleunda MP, Rublo ML, Margalet I, Lezand A, Gallego J, Ribera JM. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost. 2000; 84: 559–564.[Medline] [Order article via Infotrieve]
79. Gonzalez-Fajardo JA, Arreba E, Castrodeza J, Perez JL, Fernandez L, Agundez I, Mateo AM, Carrera S, Gutierrez V, Vaquero C. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg. 1999; 30: 283–292.[CrossRef][Medline] [Order article via Infotrieve]
80. Monreal M. Long-term treatment of venous thromboembolism with low-molecular-weight heparin. Curr Opin Pulm Med. 2000; 6: 326–329.[CrossRef][Medline] [Order article via Infotrieve]
81. Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med. 2001; 111: 130–139.[Medline] [Order article via Infotrieve]
82. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med. 2002; 162: 1729–1735.
83. Lopez-Beret P, Orgaz A, Fontcuberta J, Doblas M, Martinez A, Lozano G, Romero A. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg. 2001; 33: 77–90.[Medline] [Order article via Infotrieve]
84. Kakkar VV, Gebska M, Kadziola Z, Saba N, Carrasco P, for the Bemiparin Investigators. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost. 2003; 89: 674–680.[Medline] [Order article via Infotrieve]
85. Prandoni P. Heparins and venous thromboembolism: current practice and future directions. Thromb Haemost. 2001; 86: 488–498.[Medline] [Order article via Infotrieve]
86. Brandjes DP, Buller HR, Huisman MV, de Rijk M, Jagt H, ten Cate JW. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 1997; 349: 759–762.[CrossRef][Medline] [Order article via Infotrieve]
87. Kahn SR, Shrier I, Azoulay L, Haber M, Hirsch A. Exercise function after deep vein thrombosis in patients with and without post-thrombotic syndrome. Blood. 2000; 96 (suppl): 438a. Abstract 2793.
This article has been cited by other articles:
 |
|
 |
|
  J. Broderick, S. Connolly, E. Feldmann, D. Hanley, C. Kase, D. Krieger, M. Mayberg, L. Morgenstern, C. S. Ogilvy, P. Vespa, et al. REPRINT: Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, October 16, 2007; 116(16): e391 - e413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Broderick, S. Connolly, E. Feldmann, D. Hanley, C. Kase, D. Krieger, M. Mayberg, L. Morgenstern, C. S. Ogilvy, P. Vespa, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke, June 1, 2007; 38(6): 2001 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Gerber, S. A. Grossman, and M. B. Streiff Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors J. Clin. Oncol., March 10, 2006; 24(8): 1310 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Fukuda, K. Fukui, M. Minakawa, M. Koyama, I. Ichinoseki, and Y. Suzuki Rescue Surgical Embolectomy for Fatal Pulmonary Embolism in Patient With Intracranial Hemorrhage Ann. Thorac. Surg., February 1, 2006; 81(2): 735 - 737. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||